At SCRI, we believe participation in a clinical trial should be the first option in fighting cancer, not the last.®

The Science of Collaboration Begins with Us

We partner with pharmaceutical and biotech companies, physicians and patients to advance the science of cancer treatments.

Sarah Cannon Research Institute (SCRI) is a global leader in oncology research, conducting clinical trials in the community for more than 30 years. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country. Our contributions to pivotal research have helped to advance the majority of new cancer therapies approved by the FDA today.


Meet Our Leaders

250 plus

locations in 24 states

one in five

patients with cancer treated by SCRI and its affiliated sites

1300 plus

research physicians

Learn More About Our Offerings
1000 plus

trials actively enrolling

registered patients participating in trials yearly

first-in-human trials conducted since inception

Get to Know SCRI Leaders